Zhuhai Sailong Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of September 2024: 1.19%

Zhuhai Sailong Pharmaceutical Co Ltd asset resilience ratio. Zhuhai Sailong Pharmaceutical Co Ltd (002898) has an Asset Resilience Ratio of 1.19% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Zhuhai Sailong Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥10.00 Million
≈ $1.46 Million USD Cash + Short-term Investments

Total Assets

CN¥841.08 Million
≈ $123.08 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Zhuhai Sailong Pharmaceutical Co Ltd (2020–2023)

Asset resilience ratio of Zhuhai Sailong Pharmaceutical Co Ltd from 2020 to 2023. This chart shows how Zhuhai Sailong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 002898 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Zhuhai Sailong Pharmaceutical Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥10.00 Million 1.19%
Total Liquid Assets CN¥10.00 Million 1.19%

Asset Resilience Insights

  • Limited Liquidity: Zhuhai Sailong Pharmaceutical Co Ltd maintains only 1.19% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhuhai Sailong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Zhuhai Sailong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Zhuhai Sailong Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2020–2023)

Zhuhai Sailong Pharmaceutical Co Ltd asset resilience ratio by year from 2020 to 2023. The table below shows the annual Asset Resilience Ratio data for Zhuhai Sailong Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.26% CN¥2.14 Million
≈ $313.68K
CN¥813.84 Million
≈ $119.09 Million
+2.33pp
2022-12-31 -2.07% CN¥-17.52 Million
≈ $-2.56 Million
CN¥847.99 Million
≈ $124.09 Million
-0.04pp
2021-12-31 -2.03% CN¥-17.89 Million
≈ $-2.62 Million
CN¥882.78 Million
≈ $129.18 Million
--
2020-12-31 0.00% CN¥0.00
≈ $0.00
CN¥813.96 Million
≈ $119.11 Million
--
pp = percentage points

About Zhuhai Sailong Pharmaceutical Co Ltd

SHE:002898 China Biotechnology
Market Cap
$9.53 Million
CN¥65.12 Million CNY
Market Cap Rank
#27045 Global
#4745 in China
Share Price
CN¥0.37
Change (1 day)
-2.63%
52-Week Range
CN¥0.32 - CN¥14.65
All Time High
CN¥29.47
About

Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more